Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 17Etoposide 10fludarabine 9Whole-Body Irradiation 9Brentuximab Vedotin 9Melphalan 8fludarabine phosphate 7Vincristine 7Mycophenolic Acid 7Gemcitabine 7Doxorubicin 7Prednisone 6Granulocyte Colony-Stimulating Factor 6Busulfan 6Vorinostat 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Filgrastim 5Cytarabine 5Bortezomib 5romidepsin 4pembrolizumab 4duvelisib 4Tacrolimus 4Stem Cell Transplantation 4Carmustine 4etoposide phosphate 3Sirolimus 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell × 7-hydroxystaurosporine × Clear all
NCT00082017 2017-05-15

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
20 enrolled 13 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡